文献速递银屑病与炎症性皮肤病

银屑病生物制剂治疗与精神疾病无关联:电子病历队列研究

Lack of association of biologic therapy for psoriasis with psychiatric illness: An electronic medical records cohort study.
PubMed 文献 · J Am Acad Dermatol · 2019-05-02

该回顾性电子病历队列研究探讨银屑病患者或暴露于生物制剂者是否更易发生精神疾病。结果显示银屑病患者精神疾病风险增加,但接受生物制剂者较未接受者精神疾病诊断风险显著降低(HR 0.52,95%CI 0.51-0.53,P<.0001),与甲氨蝶呤比较亦证实(HR 0.80,95%CI 0.76-0.84,P<.0001)。局限性为治疗选择偏倚。

要点

  • 银屑病患者精神疾病风险增加。
  • 生物制剂治疗者精神疾病风险降低。
  • 与甲氨蝶呤比较结果一致。

核心结论

  • 银屑病患者多种内科及精神疾病风险增加,但接受生物制剂者精神疾病风险不增加。

研究设计与样本

  • 回顾性电子病历队列研究,比较银屑病患者与无银屑病人群,以及生物制剂暴露与否。

主要发现

  • 银屑病患者较无银屑病者更常有心血管疾病、抑郁、自杀等病史。
  • 接受生物制剂者较未接受者精神疾病诊断风险显著降低(HR 0.52,95%CI 0.51-0.53,P<.0001)。
  • 生物制剂与甲氨蝶呤比较,精神疾病风险亦降低(HR 0.80,95%CI 0.76-0.84,P<.0001)。

关键数值与推荐

  • 任何精神疾病诊断风险比:生物制剂 vs 无生物制剂为0.52(95%CI 0.51-0.53,P<.0001)。
  • 生物制剂 vs 甲氨蝶呤为0.80(95%CI 0.76-0.84,P<.0001)。

临床怎么用

  • 银屑病患者应关注精神疾病共病,生物制剂治疗未显示增加精神疾病风险。

局限性

  • 研究结果可能受治疗选择偏倚影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis and biologic therapies have been associated with psychiatric illnesses. OBJECTIVE: To determine if persons with psoriasis or those exposed to biologics are more likely to develop a psychiatric illness. METHODS: Retrospective electronic medical records cohort study. RESULTS: Individuals with psoriasis were significantly more likely to have a history of several medical (eg, cardiovascular illnesses) and psychiatric (eg, depression, suicide) illnesses than those without psoriasis. Those with psoriasis who were prescribed a biologic therapy were significantly less likely than those with psoriasis not prescribed a biologic agent to receive a psychiatric illness diagnosis (hazard ratio for any psychiatric illness 0.52, 95% confidence interval 0.51-0.53, P < .0001). With respect to any psychiatric illness, this finding was confirmed when comparing biologic therapy versus methotrexate treatment (0.80, 95% confidence interval 0.76-0.84, P < .0001). LIMITATIONS: These findings were likely attributable to treatment selection bias. CONCLUSION: Individuals with psoriasis have an increased risk of several medical and psychiatric illnesses. Individuals with psoriasis prescribed biologic agents are less likely than those not prescribed biologic agents to develop psychiatric illnesses. Most likely because of treatment selection, individuals with psoriasis prescribed biologic therapy are not currently at increased risk of a psychiatric outcome.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Margolis DJ, Shin D, Noe MH, et al. Lack of association of biologic therapy for psoriasis with psychiatric illness: An electronic medical records cohort study. J Am Acad Dermatol. 2019. PMID: 31054973. doi:10.1016/j.jaad.2019.04.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。